Skip to main content
Hualan Biological Engineering Inc. logo

Hualan Biological Engineering Inc. — Investor Relations & Filings

Ticker · 002007 ISIN · CNE000001JN8 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,526 across all filing types
Latest filing 2023-08-14 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 002007

About Hualan Biological Engineering Inc.

https://www.hualanbio.com

Hualan Biological Engineering Inc. is a biopharmaceutical enterprise specializing in the research, development, production, and commercialization of blood products and vaccines. The company’s portfolio is divided into two primary segments: plasma-derived therapeutics and viral vaccines. Key blood products include human albumin, intravenous immunoglobulin (IVIG), human coagulation factor VIII, and prothrombin complex. In the vaccine sector, the company produces seasonal influenza vaccines, including quadrivalent formulations, as well as hepatitis B and rabies vaccines. Hualan Biological Engineering operates advanced manufacturing facilities and plasma collection centers, focusing on high-quality standards and technological innovation in recombinant protein drugs and monoclonal antibodies to address critical medical needs in immunology, hematology, and infectious disease prevention.

Recent filings

Filing Released Lang Actions
关于公司取得单采血浆许可证的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement regarding the company obtaining a single plasma collection license from a health authority. It contains no financial data, no report or presentation, and is primarily an official notification about a regulatory approval. The document length is only 484 characters, indicating it is a brief announcement rather than a detailed report. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about a license acquisition, which fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2023-08-14 Chinese
关于参股公司子公司取得药物临床试验批准通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (632 characters) regarding the receipt of a drug clinical trial approval notice by a subsidiary company. It does not contain financial data, detailed reports, or regulatory certifications. It is an update on a specific event related to drug development approval, not a financial report or management change. The document is an official announcement informing investors about the clinical trial approval and associated risks. Given its nature and length, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-07-06 Chinese
关于参股公司取得药品注册受理通知书的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement (510 characters) from a company about its associate company receiving a drug registration acceptance notice from a regulatory authority. It contains no financial data, no detailed report, and no mention of financial results or management changes. It is an official announcement about a regulatory event related to product registration. The document is not a report, transcript, or financial filing but a regulatory announcement informing investors about a development. Therefore, it fits best under Regulatory Filings (RNS).
2023-07-06 Chinese
2022年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is an announcement regarding the implementation of the 2022 annual dividend distribution plan approved at the 2022 Annual General Meeting held on April 21, 2023. It details the dividend amount, payment dates, shareholder eligibility, and tax treatment. The document does not contain full financial statements or comprehensive financial performance data but focuses solely on dividend distribution details. The document length is short (1669 characters) and is clearly an announcement of dividend amount and payment details rather than a full report. Therefore, it fits the category of Notice of Dividend Amount (DIV).
2023-06-06 Chinese
关于控股子公司药品生产许可证变更暨吸附破伤风疫苗投产的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by a company regarding a change in the drug production license of its subsidiary and the commencement of production of a new vaccine product. It includes details about the license change, production lines, and potential impact on the company. The document is short (1012 characters) and does not contain financial statements, earnings data, or detailed financial analysis. It is an operational update related to regulatory approval and production capability rather than a financial report or management discussion. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing about compliance or officer certification. The document is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about a license change and production update that does not fit other specific categories.
2023-06-02 Chinese
关于公司取得单采血浆许可证的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the acquisition of single plasma collection licenses for three plasma collection stations. It includes details such as license numbers, business scope, and validity periods. The document is short (855 characters) and does not contain financial data, management changes, voting results, or regulatory certifications. It is an official announcement about a regulatory approval/license acquisition, which does not fit into financial reports, management changes, or other specific categories. Therefore, it best fits into the Regulatory Filings (RNS) category as a general regulatory announcement that does not neatly fit elsewhere.
2023-05-30 Chinese

Browse filings by year

23 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.